1,721,056 research outputs found
Evaluation of an automated-system for identification of anaerobic bacteria
No full textA fully automated computer-assisted system (ATB system, bioMerieux, France) which uses disposable microenzymatic panels was evaluated for its ability to identify 215 strains of anaerobic bacteria (clinical isolates and reference strains). All strains were examined using conventional identification protocols and by gas chromatographic analysis of short-chain fatty acids. Automated reading of Rapid ID32A test kits (bioMerieux, France) by the ATB system gave correct identification for 195 strains (90.7%): 92.25% of gram-negative anaerobes (116 strains) and 89% of gram-positive anaerobes (99 strains) were correctly identified. Twelve strains (5.6%) were incorrectly identified and 8 strains (3.7%) were not identified by the system. For some strains in the Bacteroides fragilis group, for Clostridium difficile and for the Fusobacterium genus, additional tests suggested by the ATB software were necessary to reach a final identification at the species or genus level. On the basis of the high incidence of correct identifications and the comparison of these results with those obtained previously using other commercially available kits, the ATB system was found to be a reliable method for identification of anaerobic bacteria in clinical laboratories
Utilization of computer assisted SDS-PAGE in bacterial identification and epidemiological tracing
No full textResponse to sequential treatment with lymphoblastoid interferon-α in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-α (rIFNα2a) and neutralizing-rIFNα2a antibodies negative
No full textNine Ph+ CML patients in chronic phase who were hematologically and/or karyotypically unresponsive to recombinant-IFNα2a (rIFNα2a) and neutralizing-rIFNα2a Abs negative were shifted from rIFNα2a to lymphoblastoid-IFNα (IFNα-Ly) therapy. After 3 months of IFNa-Ly treatment, the hematologic response was reinduced in 3 out of the 6 pts who were resistant to previous rIFNα2a therapy, and was maintained in 2 out of 3 patients who were hematologically but not karyotypically responsive to rIFNα2a. After 6 and 12 months, the hematologic response was progressively lost, being present only in 3 out of 7 and in 2 out of 3 evaluable patients respectively. None of the hematologically responsive patients achieved a karyotypic response (Ph neg. metaphases = 0%). One patient, who was hematologically responsive, continued being treated with IFNα-ly for 36 months but he did not achieve any karyotypic response. The results of this study suggest that in the unresponsive and neutralizing-rIFNα2a Abs negative CML patients a change in therapy, by using a non cross-reactive type of IFNα, would not be advantageous
ST2 marker might help to stratify in-hospital high risk patients with Tako-tsubo cardiomyopathy
No full textST2 marker might help to stratify in-hospital high risk patients with Tako-tsubo cardiomyopathy
No full text
Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon- alpha (rIFN alpha 2a) and neutralizing rIFN alpha 2a antibobies negative.
No full text- …
